Pórszász, RóbertMordehai, Orel-Guta Jr2018-09-262018-09-262017-04-28http://hdl.handle.net/2437/257245IBD is an idiopathic, chronic inflammation resulting from UC or CD. During the last decades biological therapy revolutionized the treatment options for moderate to severe CD and UC that is refractory to conventional treatment. . These monoclonal antibodies, which target TNF, integrins or IL12/23, have been approved for IBD.58enIBDInflammatory boweldiseasesCrohn’s diseas ulcerative colitistumor necrosis factoranti-integrininterleukin(IL)-23/IL-1Biological treatmentInfliximabadalimumabCertolizumab pegolGolimumabNatalizumabVedolizumabUstekinumabDEENK Témalista::Orvostudomány